Zoetis Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Zoetis Inc. on June 13, 2013. The report details the adoption of a new executive compensation plan effective July 1, 2013, following the company's separation from Pfizer Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the establishment of a nonqualified deferred compensation plan.
Material Changes
The primary material change is the adoption of the Zoetis Supplemental Savings Plan (SSP) by the Chief Human Resources Officer on June 13, 2013. This plan is designed to provide benefits to a select group of management or highly compensated employees who are adversely affected by Internal Revenue Code limitations on tax-qualified savings plans.
- Eligibility: All named executive officers are eligible. Participants are those in the tax-qualified Zoetis Savings Plan affected by the $255,000 compensation limit for 2013.
- Deferral Limits: Participants may defer up to 30% of compensation exceeding the $255,000 limit. Named executive officers may defer an additional 60% of bonus compensation in excess of the limit.
- Company Match: The Company matches elective deferrals at 100% of the first 5% of compensation. No match is provided for the additional 60% bonus deferral.
- Vesting: Elective deferrals are 100% vested. Company matching and profit sharing contributions vest at the same rate as the tax-qualified Savings Plan (20% per year of service).
- Funding Status: The plan is unfunded. The Company is not required to set aside assets unless a change of control occurs, at which point a trust must be fully funded.
- Transferred Amounts: Liabilities from prior Pfizer, Pharmacia, and Wyeth deferred compensation plans are being transferred to the SSP with 100% vesting.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or management commentary on operational performance. The primary contingency noted is the requirement to fully fund the plan upon a change of control. The distribution of benefits generally occurs upon termination of service, death, or disability.
Key Facts for Investor Verification
- Verify the total number of employees eligible for the SSP and the estimated aggregate deferral amounts.
- Confirm the specific vesting schedule for profit sharing contributions under the parallel tax-qualified Savings Plan.
- Review the full text of the SSP (to be filed on Form S-8) for complete terms regarding investment options and distribution elections.
- Monitor the status of the "Transferred Amounts" from Pfizer to ensure accurate accounting of legacy liabilities.